scholarly journals Quantified postsurgical small cell size CTCs and EpCAM+ circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse

2018 ◽  
Vol 412 ◽  
pp. 99-107 ◽  
Author(s):  
Liang Wang ◽  
Yilin Li ◽  
Jing Xu ◽  
Aiqun Zhang ◽  
Xuedong Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Stem Cells ◽  
Cell Size ◽  
Small Cell ◽  
Tumor Stem Cells ◽  
Cytogenetic Abnormalities ◽  
Cancer Relapse ◽  
Small Cell Size

Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma

Tumor Biology ◽  
2015 ◽  
Vol 36 (7) ◽  
pp. 5353-5360 ◽  
Author(s):  
Liang Zhu ◽  
Wei Zhang ◽  
Jianhua Wang ◽  
Rong Liu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Stem Cells ◽  
Tumor Stem Cells

Morphologies of Low-Density Cellular Materials

MRS Bulletin ◽  
1990 ◽  
Vol 15 (12) ◽  
pp. 21-23
Keyword(s):  
Spatial Scale ◽  
Cell Size ◽  
Cellular Materials ◽  
Small Cell ◽  
Low Density ◽  
Foam Structure ◽  
Standard Nomenclature ◽  
Small Cell Size ◽  
Simple Models

This section will provide a background for understanding and visualizing the microstructures observed in LDMMs. The word microcellular means small cell size, or more generally (because most low-density materials are not composed of easily recognizable “cells”) some measure of the spatial scale of the foam structure. The concept, measurement, and significance of cell size is intrinsically connected to the morphology, as are certain properties (e.g., stiffness). These matters are covered in later sections. As a background, this article describes some of the structural morphologies of low-density foams, not all of them available as LDMMs (i.e., simultaneously low-density and microcellular.) Interested readers are encouraged to also examine References 1 and 2 because a detailed discussion would take us too far afield. Instead, we shall indicate how most low-density morphologies may be considered in terms of a few simple models of morphological types encountered and how they arise. Often these are seen most cleanly in large-celled foams. Note that these are simplifications—there is no standard nomenclature.

Prediction of neoadjuvant chemotherapeutic efficacy by CTC and cfDNA in patients with locally advanced breast cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 551-551
Author(s):  
Ge Ma ◽  
Jingyi Wang ◽  
Xiaoan Liu ◽  
Tiansong Xia ◽  
Shui Wang
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cell Size ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Roc Curves ◽  
Small Cell ◽  
Advanced Breast ◽  
Dna Integrity ◽  
Small Cell Size

551 Background: Neoadjuvant chemotherapy (NCT) is the standard treatment for patients with locally advanced breast cancer (LABC). Liquid biopsy, including circulating tumor cells (CTCs) and cell free DNA (cfDNA) represent an important paradigm shift in precision medicine. The aim of this study was to estimate the value of CTCs and cfDNA in efficacy prediction of the response to NCT in patients with LABC. Methods: Patients with LABC received EC4-T4 regimen NCT. CTCs and cfDNA obtained at time of biopsy, after first course of NCT and after the last course of NCT. All patients were divided into two groups according to pathological reactivity. A novel SE-iFISH strategy, improved for detection of CTCs, was applied. CTCs(CD45-/CD31-) with different cytogenetic abnormality of aneuploid chromosome 8 and small cell size CTCs (≤5 mm of WBCs) were analyzed separately in LABC patients subjected to NCT for the first time. Plasma DNA biomarkers ALU 111 and ALU 260 elements were evaluated using qRT-PCR. DNA integrity was calculated relative to the breast cancer cell line MCF-7. Clinical significance of diverse subtypes of CTCs and cfDNA was systematically investigated. Results: A total of 45 patients was enrolled in this study. According to the therapy response, 6/45 patients had high response (High-R) and 39/45 patients had low response (Low-R). There were no significant differences in CTC number and small cell size CTC number between High-R and Low-R groups in all three detections. However, the CTC number kept stable in the High-R group, but increased continually during NCT in Low-R group. In 45 patients, the percentage of CTCs with trisomy 8, which were related to cancer metastasis, incresed in the Low-R group at the third dectection. The concentration of cfDNA in all three detections did not indicate outcome of NCT. However, concentration of ALU 111 increased in Low-R patients during NCT. In High-R patients, no significant increase was observed. A CTC and cfDNA panel were constructed to discriminate High-R patients from Low-R patients. The areas under the receiver-operating characteristic (ROC) curves of the pannel for the three times were 0.803, 0.859 and 0.667, respectively. DNA integrity index(CFDI) was significantly higher in High-R group than Low-R after first course of NCT. The areas under the ROC curves of the CFDI for the three times were 0.675, 0.863 and 0.697, respectively. Conclusions: The trend of cfDNA concentration changed resembled to the number of CTCs, small cell size CTCs and triploid CTCs during NCT, and could predict tumor response to ongoing treatment.

scholarly journals HCG18 Participates in Vascular Invasion of Hepatocellular Carcinoma by Regulating Macrophages and Tumor Stem Cells

2021 ◽  
Vol 9 ◽  
Author(s):  
Liwei Zhang ◽  
Zhiwei Wang ◽  
Mingxing Li ◽  
Peng Sun ◽  
Tao Bai ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Stem Cells ◽  
Stem Cell ◽  
Transcription Factors ◽  
Immune Checkpoint ◽  
Vascular Invasion ◽  
Tumor Stem Cell ◽  
Tumor Stem Cells ◽  
Immune Microenvironment ◽  
Core Genes

ObjectivesTo identify key genes involved in vascular invasion in hepatocellular carcinoma (HCC), to describe their regulatory mechanisms, and to explore the immune microenvironment of HCC.MethodologyIn this study, the genome, transcriptome, and immune microenvironment of HCC were assessed by using multi-platform data from The Cancer Genome Atlas (n = 373) and GEO data (GSE149614). The key regulatory networks, transcription factors and core genes related to vascular invasion and prognosis were explored based on the CE mechanism. Survival analysis and gene set enrichment were used to explore pathways related to vascular invasion. Combined with single-cell transcriptome data, the distribution of core gene expression in various cells was observed. Cellular communication analysis was used to identify key cells associated with vascular invasion. Pseudo-temporal locus analysis was used to explore the regulation of core genes in key cell phenotypes. The influence of core genes on current immune checkpoint therapy was evaluated and correlations with tumor stem cell scores were explored.ResultsWe obtained a network containing 1,249 pairs of CE regulatory relationships, including 579 differential proteins, 28 non-coding RNAs, and 37 miRNAs. Three key transcription factors, ILF2, YBX1, and HMGA1, were identified, all regulated by HCG18 lncRNA. ScRNAseq showed that HCG18 co-localized with macrophages and stem cells. CIBERSORTx assessed 22 types of immune cells in HCC and found that HCG18 was positively correlated with M0 macrophages, while being negatively correlated with M1 and M2 macrophages, monocytes, and dendritic cells. Cluster analysis based on patient prognosis suggested that regulating phenotypic transformation of macrophages could be an effective intervention for treating HCC. At the same time, higher expression of HCG18, HMGA1, ILF2, and YBX1 was associated with a higher stem cell score and less tumor differentiation. Pan cancer analysis indicated that high expression of HCG18 implies high sensitivity to immune checkpoint therapy.ConclusionHCG18 participates in vascular invasion of HCC by regulating macrophages and tumor stem cells through three key transcription factors, YBX1, ILF2, and HMGA1.

scholarly journals Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Yang Hong ◽  
Jiahui Si ◽  
Jie Zhang ◽  
Ying Xiong ◽  
Jianzhi Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Size ◽  
Cell Lung Cancer ◽  
Large Cell ◽  
Small Cell ◽  
Chromosome 8 ◽  
Small Cell Lung ◽  
Post Surgery ◽  
Small Cell Size

ObjectiveThe size distribution of circulating aneuploid cells (CACs) and its clinical significance were investigated in resectable non-small cell lung cancer (NSCLC).Patients and MethodsA total of 50 patients with resectable NSCLC were enrolled in this study. Blood samples (50 pre-surgery and 35 post-surgery) were collected and used for the detection of CAC chromosome 8 heteroploidy through the subtraction enrichment and immunostaining fluorescence in situ hybridization (SE-iFISH) method.ResultsLess than 20% small cell size and more than 80% large cell size CACs were detected. Karyotypes, including triploid, tetraploid, and multiploid, had varying distributions. The triploid subtype accounted for the majority of small cell size CACs, whereas the multiploid subtype accounted for the majority of large cell size CACs. We found that total small cell size and triploid small cell size CACs, but not large cell size CACs, derived from pre-surgery samples, were associated with shorter disease-free survival. Moreover, total small cell size and triploid small cell size CACs were associated with higher TNM stage and recurrence. Nevertheless, the variation between pre- and post-surgery CACs was not related to survival among patients with resectable NSCLC.ConclusionsPre-surgery small cell size CACs, especially the triploid subtype, could be regarded as a potential prognostic biomarker for patients with resectable NSCLC.

Sign in / Sign up

Export Citation Format

Share Document